NoelleVirginiaFreyMD

Associate Professor of Medicine, University of Pennsylvania, Clinical Director of Cellular Therapy, Cell Therapy and Transplant

Join to view full profile

Dr. Frey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frey's full profile

Already have an account?

Office
3400 Spruce St
1 Maloney Building
Philadelphia, PA 19104
Phone+1 215-662-3957

Summary

Dr. Noelle Frey is an oncologist in Philadelphia, PA and is affiliated with Hospital of the University of Pennsylvania. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 16 years. She is experienced in hematologic oncology, with an expertise in CAR T cell therapy and stem cell transplantation.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Pennsylvania Health SystemResidency, Internal Medicine, 2001 - 2004
Columbia University Vagelos College of Physicians and SurgeonsClass of 2001

Certifications & Licensure

PA State Medical License 2001 - 2024
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy Start of enrollment: 2010 Mar 17
Completed
Phase 1
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 Jun 01
Terminated
Phase 1, Phase 2
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
Completed
Phase 2
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission Start of enrollment: 2012 Jul 01
Terminated
Phase 1, Phase 2
Dose Optimization Trial of CD19 Redirected Autologous T Cells Start of enrollment: 2013 Jan 02
Completed
Phase 2
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2014 Feb 27
Completed
Phase 2
Study of Efficacy and Safety of CTL019 in Adult ALL Patients Start of enrollment: 2016 Jun 01
Withdrawn
Phase 2
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL Start of enrollment: 2016 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10
2 citations
Cytokine-mediated CAR T therapy resistance in AML.
Anand S Bhagwat, Leonel Torres, Olga Shestova, Maksim Shestov, Patrick W Mellors
Nature Medicine. 2024-12-01
Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review.
Connor B Grady, Yimei Li, Shannon L Maude, Elizabeth O Hexner, Noelle V Frey
Transplantation and Cellular Therapy. 2024-11-26

Journal Articles

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium Difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients
Edward A Stadtmauer, James K Mangan, Elizabeth O Hexner, David L Porter, Daria V Babushok, Jacqueline Smith, Craig W Freyer, Mindy Schuster, Noelle V Frey, Selina M Lu..., Clinical Infectious Diseases

Abstracts/Posters

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Noelle V. Frey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
Noelle V. Frey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
Noelle V. Frey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Noelle V. Frey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
Noelle V. Frey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
Noelle V. Frey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Press Mentions

The COVID-19 Vaccine Doesn’t Fully Protect People like Me Who Are Immuno-Compromised. Science Is Working on ItJune 21st, 2021
Measuring MRD Imperative to Guide ALL Treatment DecisionsOctober 16th, 2019
OncLive® Presents State of the Science Summit™ on the Treatment of Hematologic MalignanciesSeptember 10th, 2019
Join now to see all